Evolus reports Phase III data for prabotulinumtoxinA in glabellar lines

In October, the Evolus Inc. unit of the Alphaeon Corp. subsidiary of Strathspey Crown Holdings LLC (Newport Beach, Calif.) reported data from 654 patients with glabellar lines (frown lines between the eyebrows) in the Phase III EV-001 and EV-002 trials showing that prabotulinumtoxinA (DWP-450) met the primary endpoint in both trials of increasing responder rates at day 30 vs. placebo. Specifically, the product led to responder rates of 67.5% and 70.4% in EV-001 and EV-002, respectively.

A responder was defined as achieving a ≥2-point composite improvement of glabellar lines as measured by the Glabellar Line Scale at maximum frown. A composite score required both the investigator and the subject to independently agree that there had been a ≥2-point improvement at day 30 compared to baseline...